Clinical Trials Available

Expedition 3 Study

Protocol H8A-MC-LZAX. Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY20624030) Versus Placebo

IRB Number: 2013-9700

Condition/Disease: Alzheimer’s

Lead Researcher: Aimee Pierce, MD

Location:

UC Irvine Campus  (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall, Brain Imaging Center in Irvine Hall).

Purpose:

To evaluate the effectiveness and long-term safety of immunization treatment with solanezumab versus placebo in patients with mild Alzheimer’s disease.

Eligibility:

Patients with probable Alzheimer’s disease at the mild stage.

Time Commitment:

22 visits over the course of up to 80 weeks total (~ 1.5 years).

Benefits:

You may or may not receive any benefit from being in this study. If you are in the group that receives the study drug solanezumab, and it proves to treat your condition better than placebo, you may benefit from participating in the study, but this cannot be guaranteed. While researchers hope solanezumab will be better than other available treatments, there is no proof of this yet. If you take part in this study, other people with AD may be helped.

You may receive information from physical examinations, laboratory tests, or other testing that is done in this study but these tests may not have any impact on your health.

The information collected from this study may increase knowledge regarding the treatment of Alzheimer’s disease and help people in the future.

Compensation:

You will not be compensated for your participation in this research study. If you have to travel some distance to the study site, a maximum of $40 will be provided for each visit required for the study.

Contact Name: Beatriz Yanez, RN, Clinical Research Nurse and Coordinator

Phone: 949-824-3250

Email: byanez@uci.edu

Study Website: https://www.expedition3study.com/

HarmonyAD Study

A prospective, randomized, double-blind, placebo-controlled, phase 2 efficacy and safety study of oral ELND005 for treatment of agitation and aggression in patients with moderate to severe Alzheimer’s disease

Condition/Disease: Alzheimer’s

Lead Researcher: Aimee L. Pierce, MD

Location:

UCI MIND at Gottschalk Medical Plaza and ICTS at Hewitt Hall

Purpose:

The HarmonyAD clinical study is being conducted to determine if an investigational drug given as a pill can safely reduce the symptoms of aggression and agitation in people with Alzheimer’s disease.

Eligibility:

Alzheimer’s disease is frustrating. Sudden outbursts of anger, aggression or agitation are all part of the Alzheimer’s disease process. Managing these symptoms can be difficult. But you are not alone. Doctors are working daily to find treatments.

To take part in this study, individuals must:

• Be at least 50 years old

• Have a diagnosis of Alzheimer’s disease

• Experience at least moderate agitation and/or aggression

• Exhibit agitation and/or aggression at least once a week

• Have a study partner, informant or caregiver who is willing to participate in the study

Time Commitment:

The study will last approximately five and a half months (three months of active treatment with study drug or placebo). In total, participants will attend seven clinic visits, four telephone contact visits and be monitored throughout the study.

Benefits:

There may be no direct health benefits to you for participating in this study. You may get placebo, which means that you will not be taking active drug. If you are in the group the receives the study drug (ELND005, scylloinositol) and it proves to treat your condition better than placebo, you may benefit from participating in the study, but this cannot be guaranteed. The information collected from this study may increase knowledge regarding the treatment of Alzheimer’s disease and help people in the future.

You may receive information from routine testing that is done in this study, but these tests may not have any impact on your health.

Compensation:

The investigational product and study-related procedures will be provided at no cost. For participants who travel some distance to the study site, a maximum of $30 will be provided for each visit required for the study.

Contact Name: Beatriz Yanez, RN

Phone: 949-824-3250

Email: byanez@uci.edu

Study website: http://www.harmonyadstudy.com/

A4 Study

Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)

Condition/Disease: Alzheimer’s

Lead Researcher: Aimee L. Pierce, MD

Location:

UCI Campus (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall, Newport Diagnostic Center, CARE Clinic in Laguna Woods)

Purpose:

To evaluate whether immunization treatment with solanezumab versus placebo will slow cognitive decline in individuals showing the presence of elevated protein called amyloid on a brain scan.

Eligibility:

Male and female participants, ages 65-85 years old, with evidence of elevated brain amyloid pathology on a brain scan.

Time Commitment:

Screening phase (up to 90 days) and treatment phase (48 visits over the course of 168 weeks or ~3 years)

Benefits:

You may or may not receive any benefit from being in this study. If you are in the group that receives the study drug, solanezumab, and it proves to treat your condition better than placebo, you may benefit from participating in the study, but this cannot be guaranteed.

The information collected from this study may increase knowledge regarding the treatment of Alzheimer’s disease and help people in the future.

Compensation:

Participants are eligible to receive the following compensation in cash during the course of this study:

• $100 for each completed MRI scan; there are 4 MRI scans ($400 max).

• $100 for each completed PET scan; there are 2 PET scans ($200 max).

• $100 for each completed lumbar puncture; there are two optional lumbar punctures ($200 max).

• $50 for each infusion visit requiring infusion; there are 42 infusion visits in this study ($2100 max).

The grand total compensation for this study is a maximum of $2900 in cash.

Participants will also be reimbursed $40 in cash for travel-related expenses for each visit required for the study.

Contact Name: Beatriz Yanez, RN

Phone: 949-824-3250

Email: byanez@uci.edu

Study website: http://a4study.org/

 

 

Contact the Clinical Trials Team

For more information about available or upcoming studies, please contact the Clinical Trials team.

Telephone: (949) 824-3250 or (949) 824-5733
Email: byanez@uci.edu

 


 

Donate